Please assess the completion status of the following clinical trial:

Trial Title: Intra-Erythrocyte Dexamethasone Sodium Phosphate in Ataxia Teleangiectasia Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* neurological signs of AT~* patients in autonomous gait or helped by a support~* proven molecular diagnosis of AT~* Males and females aged \> 3 years~* Body weight \>15 kg~* Plasma levels of Lymphocytes CD4+/mm3 \> 500 (for patients aged 3-6 years) or \> 200 (older than 6 years)~* written IC to participate.~Exclusion Criteria:~* Current or previous neoplastic disease~* History of severe impairment of the immunological system~* Chronic conditions representing a contraindication to the use of steroid drugs~* Non compliance with the study request~* Any previous steroid assumption within 30 days before starting ERY-DEX~* Have any other significant disease that in the Investigator's opinion would exclude the patient from the trial~* Females of childbearing potential who were pregnant, breast-feeding or were not using adequate contraceptive methods

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ERY-DEX (Type: EXPERIMENTAL): Patients treated with monthly treatment of ERY-DEX (dexamethasone sodium phosphate encapsulated in autologous erythrocytes)

Based on this trial design, predict the completion outcome and termination type (if applicable).